The "Atrial Fibrillation Drugs Market By Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026" report has been added to Acumen Research and Consulting's offers.

Pune, India -- (SBWire) -- 05/10/2019 --The Global Atrial Fibrillation Drugs Market is estimated to grow at CAGR above 3.4 % over the forecast time frame 2019-2026 and reach the market value around USD 17.5 billion by 2026.

Increased geriatric population worldwide is one of the biggest growth factors, because people over 65 years of age are prone to chronic conditions such as auric fibrillation, diabetes, high blood pressure etc. Moreover, the increase in cardiovascular prevalence in the United States, in particular, will boost the growth of the market for atrial fibrillation in the coming years. One of the major impending growth factors is the side effects linked to the regular intake of atrial fibrillation drugs. Side effects such as excessive bleeding, fatigue, etc. are likely to impair the growth of the market. In addition, a lack of awareness of recent pharmaceutical therapies is a further obstacle to growth.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1347

Industry Insights

The market for auricular fibrillation anticoagulants was estimated at approximately US$ 11.5 trillion in 2018. Anticoagulants have been introduced in order to reduce atrial fibrillation in people with stroke. Anti-platelet or anticoagulant therapy based on the age of the patient and the presence of other risk factors should be considered in patients with atrial fibrillation. A substantial increase in the incidence of strokes associated with auric fibrillation has increased demand for anticoagulants in recent years and increased the growth of the market for atrial fibrillations.

The use of atrial paroxysmal fibrillation medicines over the estimated period is increased to 2.9 percent. Paroxysmal atrial fibrillation occurs when the heart's electrical pathways are irregular and the heart does not pump enough oxygen-rich blood, which results in erratic cardiac rates which last up to 24 hours. In the geriature and younger generation, the occurrence of paroxysmal aural fibrillation obviously increases due to factors like valve disorders, coronary artery disease, pre-cardial surgery etc. The above reasons will therefore increase the growth of the market for atrial fibrillation drugs.

In 2018 the use of the cardiac rhythm control market for atrial fibrillation drug was estimated at USD 3.3 billion. The control of cardiac rhythm consists of maintenance and acute restoration of sinus rhythm in atrial fibrillation patients. Cardiovascular control can actually lower atrial death and morbidity associated with fibrillation. There is a much higher risk of progression of arrhythmia among patients with coexisting cardiovascular conditions such as obstructive sleep apnea, hypertension, heart disease, and heart failure. The increasing incidence and geriatric population of these cardiovascular diseases therefore will increase the cardiac rhythm contrasting.

Over the forecast period, oral atrial fibrillation drug market will grow at 3.1 %. The objective of medical treatment is to prevent complication risks, maintain the rhythm of the sinus and minimize atrial fibrillation symptoms for patients with atrial fibrillation. Oral drug therapy like warfarin is the cornerstone of oral anticoagulant therapy for patients who are at high risk. As the incidence of atrial strokes worldwide increases, oral drug therapies are undergoing a upward path to market growth.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/atrial-fibrillation-drugs-market

The use of atrial medicines is estimated to increase by 3% over the forecast period in hospitals. Increased popularity in developing and development countries for anticoagulant and antiarrhythmic drugs will strongly contribute to higher demand for aura in hospitals. In addition, the growth of the auric fibrillation drug market would further expand investments and partnerships with different manufacture companies.

Regional Snapshots

The US market for atrial fibrillation drugs is the world's largest, and it is expected to expand by 2.4% over the forecast period. It will continue to increase with stable growth during the forecast period and lead the industry worldwide. The US atrial fibrillation market is supposed to be driven during projection years by increasing geriatric population, increasing investment in venture capital from manufacturing companies and increasing adoption rates of new medicinal product for severe conditions in patients under atrial fibrillation in the country.

Key Players & Strategies

The major industrial operators in the global market are Johnson & Johnson, Pfizer, Sanofi, Bavier AG, Boehringer Inglheim, Bristol-Myers Squibb, Daiichis, Sankyos and AstraZeneca. Due to their strong financial position and better brand recognition these key market players hold majority market share. These firms' main strategies in the market include launching of new products, expansion strategy, procurement strategy, and other measures to achieve a competitive advantage over their peers.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Atrial Fibrillation Drugs
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Atrial Fibrillation Drugs Market By Product
1.2.2.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.2.2. Global Atrial Fibrillation Drugs Market Revenue Share By Product in 2017
1.2.2.3. Antiarrhythmic Drugs
1.2.2.4. Anticoagulant Drugs
1.2.3. Atrial Fibrillation Drugs Market By Type
1.2.3.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.3.2. Global Atrial Fibrillation Drugs Market Revenue Share By Type in 2017
1.2.3.3. Paroxysmal
1.2.3.4. Permanent
1.2.3.5. Persistent
1.2.4. Atrial Fibrillation Drugs Market By Application
1.2.4.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.4.2. Global Atrial Fibrillation Drugs Market Revenue Share By Application in 2017
1.2.4.3. Heart Rate Control
1.2.4.4. Heart Rhythm Control
1.2.5. Atrial Fibrillation Drugs Market By Route Of Administration
1.2.5.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison By Route Of Administration (2015-2026)
1.2.5.2. Global Atrial Fibrillation Drugs Market Revenue Share By Route Of Administration in 2017
1.2.5.3. Injectable
1.2.5.4. Oral
1.2.6. Atrial Fibrillation Drugs Market By End Use
1.2.6.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.6.2. Global Atrial Fibrillation Drugs Market Revenue Share By End Use in 2017
1.2.6.3. Cardiac Centres
1.2.6.4. Hospitals
1.2.6.5. Ambulatory Surgical Centres
1.2.7. Atrial Fibrillation Drugs Market by Geography
1.2.7.1. Global Atrial Fibrillation Drugs Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.7.2. North America Atrial Fibrillation Drugs Market Revenue and Growth Rate (2015-2026)
1.2.7.3. Europe Atrial Fibrillation Drugs Market Revenue and Growth Rate (2015-2026)
1.2.7.4. Asia-Pacific Atrial Fibrillation Drugs Market Revenue and Growth Rate (2015-2026)
1.2.7.5. Latin America Atrial Fibrillation Drugs Market Revenue and Growth Rate (2015-2026)
1.2.7.6. Middle East and Africa (MEA) Atrial Fibrillation Drugs Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Atrial Fibrillation Drugs Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Atrial Fibrillation Drugs Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Atrial Fibrillation Drugs Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Atrial Fibrillation Drugs Major Manufacturers in 2017

CHAPTER 4. ATRIAL FIBRILLATION DRUGS MARKET BY PRODUCT

4.1. Global Atrial Fibrillation Drugs Revenue By Product
4.2. Antiarrhythmic Drugs
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Anticoagulant Drugs
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. ATRIAL FIBRILLATION DRUGS MARKET BY TYPE

5.1. Global Atrial Fibrillation Drugs Revenue By Type
5.2. Paroxysmal
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Permanent
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Persistent
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. ATRIAL FIBRILLATION DRUGS MARKET BY APPLICATION

6.1. Global Atrial Fibrillation Drugs Revenue By Application
6.2. Heart Rate Control
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Heart Rhythm Control
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. ATRIAL FIBRILLATION DRUGS MARKET BY ROUTE OF ADMINISTRATION

7.1. Global Atrial Fibrillation Drugs Revenue By Route Of Administration
7.2. Injectable
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Oral
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 8. ATRIAL FIBRILLATION DRUGS MARKET BY END USE

8.1. Global Atrial Fibrillation Drugs Revenue By End Use
8.2. Cardiac Centres
8.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
8.3. Hospitals
8.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
8.4. Ambulatory Surgical Centres
8.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 9. NORTH AMERICA ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

9.1. North America Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. North America Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. U.S.
9.3.1. U.S. Atrial Fibrillation Drugs Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Canada
9.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. Mexico
9.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 10. EUROPE ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

10.1. Europe Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Europe Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. UK
10.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Germany
10.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. France
10.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.6. Spain
10.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.7. Rest of Europe
10.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 11. ASIA-PACIFIC ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

11.1. Asia-Pacific Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Asia-Pacific Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. China
11.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. Japan
11.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. India
11.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.6. Australia
11.6.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.7. South Korea
11.7.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.8. Rest of Asia-Pacific
11.8.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 12. LATIN AMERICA ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

12.1. Latin America Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Latin America Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Brazil
12.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4. Argentina
12.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5. Rest of Latin America
12.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 13. MIDDLE EAST ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

13.1. Middle East Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Middle East Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. Saudi Arabia
13.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.4. UAE
13.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.5. Rest of Middle East
13.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 14. AFRICA ATRIAL FIBRILLATION DRUGS MARKET BY COUNTRY

14.1. Africa Atrial Fibrillation Drugs Market Revenue and Growth Rate, 2015 - 2026 ($Million)
14.2. Africa Atrial Fibrillation Drugs Market Revenue Share Comparison, 2015 & 2026 (%)
14.3. South Africa
14.3.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
14.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
14.4. Egypt
14.4.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
14.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
14.5. Rest of Africa
14.5.1. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
14.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)

CHAPTER 15. COMPANY PROFILE

15.1. Johnson & Johnson
15.1.1. Company Snapshot
15.1.2. Overview
15.1.3. Financial Overview
15.1.4. Product Portfolio
15.1.5. Key Developments
15.1.6. Strategies
15.2. Pfizer
15.2.1. Company Snapshot
15.2.2. Overview
15.2.3. Financial Overview
15.2.4. Product Portfolio
15.2.5. Key Developments
15.2.6. Strategies
15.3. Sanofi
15.3.1. Company Snapshot
15.3.2. Overview
15.3.3. Financial Overview
15.3.4. Product Portfolio
15.3.5. Key Developments
15.3.6. Strategies
15.4. Bayer AG
15.4.1. Company Snapshot
15.4.2. Overview
15.4.3. Financial Overview
15.4.4. Product Portfolio
15.4.5. Key Developments
15.4.6. Strategies
15.5. Boehringer Ingelheim
15.5.1. Company Snapshot
15.5.2. Overview
15.5.3. Financial Overview
15.5.4. Product Portfolio
15.5.5. Key Developments
15.5.6. Strategies
15.6. Bristol-Myers Squibb
15.6.1. Company Snapshot
15.6.2. Overview
15.6.3. Financial Overview
15.6.4. Product Portfolio
15.6.5. Key Developments
15.6.6. Strategies
15.7. Daiichi Sankyo
15.7.1. Company Snapshot
15.7.2. Overview
15.7.3. Financial Overview
15.7.4. Product Portfolio
15.7.5. Key Developments
15.7.6. Strategies
15.8. AstraZeneca
15.8.1. Company Snapshot
15.8.2. Overview
15.8.3. Financial Overview
15.8.4. Product Portfolio
15.8.5. Key Developments
15.8.6. Strategies
15.9. Others
15.9.1. Company Snapshot
15.9.2. Overview
15.9.3. Financial Overview
15.9.4. Product Portfolio
15.9.5. Key Developments
15.9.6. Strategies

CHAPTER 16. RESEARCH APPROACH

16.1. Research Methodology
16.1.1. Initial Data Search
16.1.2. Secondary Research
16.1.3. Primary Research
16.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1347

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1347

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.